文献速递甲状腺疾病

亚洲人群无分子检测时细胞学不确定甲状腺结节高比例不必要手术及采用分子检测的成本效益:一项决策分析

High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis.
PubMed 文献 · Thyroid · 2025-01-21

该研究评估香港一家三级内分泌外科中心连续Bethesda III或IV甲状腺结节的处理,发现36%接受 upfront 手术,其中72%为不必要手术;决策树模型显示常规分子检测每年可减少82例不必要手术,增量成本效益比为49102港元(6314美元)/例不必要手术,检测价格降至8044港元(1031美元)以下则具成本节约。

要点

  • 细胞学不确定结节中36%接受 upfront 手术,最终病理恶性仅28%,即72%手术不必要。
  • 常规分子检测每年可减少82例不必要手术,较当前实践多26%。
  • 增量成本效益比为49102港元(6314美元)/例不必要手术,检测成本是主要影响因素。

核心结论

  • 当前细胞学不确定甲状腺结节的不必要手术比例高;分子检测较当前实践更有效减少不必要手术但成本更高,检测成本降低后可实现成本节约。

研究设计与样本

  • 对香港一家三级内分泌外科中心连续Bethesda III或IV甲状腺结节的处理决策与结局进行评估,并构建决策树模型比较当前实践与常规分子检测的成本效益。

主要发现

  • 4年间共行2157例细针穿刺细胞学检查(FNAC),排除后分析1957例,其中18.6%为Bethesda III或IV。
  • 细胞学不确定结节中36%接受 upfront 手术,最终病理恶性占28%,即72%的手术不必要。
  • 常规分子检测每年可减少82例不必要手术,较当前实践多26%。
  • 常规分子检测的增量成本效益比为49102港元(6314美元)/例不必要手术。
  • 敏感性分析显示分子检测的检测成本对增量成本效益比贡献显著;商业价格降至8044港元(1031美元)以下时常规分子检测可节省成本。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objectives: Cytologically indeterminate thyroid nodules (Bethesda class III or IV) carry a 10-40% risk of malignancy. Diagnostic lobectomies are frequently performed but negative surgeries incur unnecessary costs on the healthcare system, potential complications, and negative impacts on quality of life. Molecular tests (MTs) have been developed to reduce unnecessary surgeries. However, well-validated, high-performance MTs are often expensive, and their cost-effectiveness has not been studied in the Asian population. This study evaluates the rate of unnecessary surgery in the setting without MT (our current practice) and the cost-effectiveness of introducing a commercially available MT for the management of cytologically indeterminate thyroid nodules in a modernized city in Asia. Methods: Management decisions and outcomes of consecutive Bethesda III or IV thyroid nodules in a tertiary endocrine surgery center in Hong Kong were evaluated. Costs of health service provided by the public health system, which covers >90% of healthcare service in the city, were retrieved. A decision tree model was developed to compare the cost-effectiveness in avoiding unnecessary surgeries of current practice versus routine MT from a public healthcare provider's perspective. In our current practice, MT was not available, and patients with indeterminate nodules received either upfront lobectomy, repeat fine needle aspiration cytology (FNAC), or active surveillance. Results: Over a 4-year period, 2157 FNACs were performed. After exclusion, 1957 FNACs were analyzed, and 18.6% were Bethesda III or IV. Thirty-six percent of these cytologically indeterminate nodules received upfront surgery, with 28% having malignancy in final pathology, that is, 72% of surgeries were unnecessary. Routine MT could reduce 82 unnecessary surgeries/year, 26% more than current practice. Routine MT resulted in an incremental cost-effectiveness ratio of Hong Kong dollar (HKD) 49,102 (US dollar [USD] 6314) per unnecessary surgery. Sensitivity analysis showed test cost of MT contributed significantly to incremental cost-effectiveness ratio. Lowering the commercial price of MT to below HKD 8044 (USD 1031) would render routine MT cost-saving. Conclusion: Currently, a high rate of unnecessary surgeries is being performed for cytologically indeterminate thyroid nodules. MT was more effective in reducing unnecessary surgeries than current practice, but at a higher cost. MT will become cost-saving if the test cost could be lowered.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Fung MHM, Tang C, Kwok GW, et al. High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis. Thyroid. 2025. PMID: 39835971. doi:10.1089/thy.2024.0436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。